Nowak KL, Farmer-Bailey H, Wang W, You Z, Steele C, Cadnapaphornchai MA, Klawitter J, Patel N, George D, Jovanovich A, Soranno DE, Gitomer B, Chonchol M: Curcumin therapy to treat vascular dysfunction in children and young adults with ADPKD: A randomized controlled trial. Clin J Am Soc Nephrol 17: , 2022.
Due to an author error, there were some errors in Table 4. The title of the table should appear as “Effects of curcumin on secondary and other outcomes.” The change within group for CRP, mg/L in the placebo group appeared as “0.17 (0.36 to 0.70)” but should instead appear as “0.17 (–0.36 to 0.70).” The change within group for IL-6, pg/ml in the placebo group appeared as “2.33 (0.91 to 1.54)” but should instead appear as “2.33 (1.89 to 2.76).” The marker in the last row is missing and should appear as “TNF-α, pg/ml.” The corrected Table 4 appears below.
Table 4. -
Effects of
curcumin on secondary and other outcomes
| Markers |
Curcumin, n=28 |
Placebo, n=29 |
Difference in Change According to Treatment Assignment |
| Baseline |
12 mo |
Change within Group |
Baseline |
12 mo |
Change within Group |
| Urinary 8-iso-prostaglandin F2α, mg/d, normalized to urinary creatinine, mg/dl, e−8
|
14.1 (8.1 to 27.6) |
14.4 (8.9 to 25.9) |
0.00 (–0.34 to 0.34) |
9.3 (6.6 to 21.7) |
12.5 (6.3 to 33.4) |
0.27 (–0.14 to 0.69) |
−0.14 (–0.61 to 0.32) |
| CRP, mg/L |
0.70 (0.18 to 2.45) |
0.63 (0.38 to 2.91) |
0.21 (–0.47 to 0.88) |
0.32 (0.19 to 0.68) |
0.44 (0.11 to 1.30) |
0.17 (–0.36 to 0.70) |
0.49 (–0.27 to 1.25) |
| IL-6, pg/ml |
0.42 (0.32 to 0.71) |
3.6 (2.6 to 7.8) |
2.24 (1.69 to 2.80) |
0.43 (0.36 to 0.76) |
4.3 (3.7 to 5.3) |
2.33 (1.89 to 2.76) |
−0.11 (–0.65 to 0.42) |
| IFN-γ, pg/ml |
3.7 (2.5 to 4.7) |
1.2 (0.93 to 2.1) |
−1.05 (–1.35 to –0.75) |
4.1 (2.9 to 6.5) |
1.2 (1.1 to 1.5) |
−1.14 (–1.41 to –0.87) |
−0.01 (0.25 to 0.22) |
| TNF-α, pg/ml |
1.34±0.54 |
0.61±0.38 |
−0.73 (–0.95 to –0.51) |
1.58±0.83 |
0.63±0.49 |
−0.95 (–1.27 to –0.63) |
0.01 (–0.22 to 0.25) |
Data are median (interquartile range) or mean (95% confidence interval) for change within group and difference in change on the basis of a complete case analysis. The difference in change across groups is the slope (95% confidence interval) derived from linear regression models after adjustment for baseline values for given variable, with the curcumin group compared with the placebo group. For all variables except TNF-α, the change within group and difference in change across groups are comparing log-transformed values. CRP, C-reactive protein.
